Sandborn William J.'s Form 4 filing
Ventyx Biosciences, Inc. (VTYX) · filed May 1, 2023
- Accession no.
- 0001209191-23-026312
- Filed
- May 1, 2023, 5:36 PM ET
- Trade date
- Apr 28, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $398.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandborn William J.CIK 0001923805 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | MOption exerciseAcquired | +10,790 | $0.20 | +$2,158 | 59,179 | Direct | |
| Apr 28, 2023 | Common Stock | SSaleDisposed | −3,886 | $36.17F2 | −$140,570.22 | 55,293 | Direct | |
| Apr 28, 2023 | Common Stock | SSaleDisposed | −6,904 | $37.40F3 | −$258,184.75 | 48,389 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | MOption exerciseDisposed | −10,790 | $0.00 | $0 | 21,419 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average share price of an aggregate total of 3,886 shares sold in the price range of $35.8292 to $36.6489. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average share price of an aggregate total of 6,904 shares sold in the price range of $36.895 to $37.61. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Medical Officer